{"ticker": {"uuid": "90c87dad-a419-4e5d-a01a-896a75a64947", "symbol": "CRMD", "name": "CorMedix Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Why (CRMD) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Cormedix Inc. (CRMD) using AI models, highlighting weak near-term sentiment but strong mid-term indicators within a broader long-term weak bias. It discusses institutional trading strategies, including long, breakout, and short positions, and provides multi-", "url": "https://news.stocktradersdaily.com/news_release/15/Why_CRMD_Price_Action_Is_Critical_for_Tactical_Trading_062126122202_1782015722.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T00:41:18", "published_display": "21 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)", "summary": "CorMedix reported strong Q1 2026 results driven by DefenCath and raised its full-year guidance, emphasizing continued business momentum despite the upcoming expiration of temporary TDAPA reimbursement. The company's investment narrative hinges on DefenCath's sustained performance", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/raised-2026-guidance-and-defencath-momentum-might-change-the", "source_name": "Simply Wall Street", "published_at": "2026-06-18T05:09:42", "published_display": "18 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (CRMD) Achieves Remarkable 384.60% Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOT1QtSUc4U3JIRVhCVWZPb2J0SkI1TktVMmRNcVphcks3QU9hblVhbjlyVl9uMTZwOTdkVUFhaFpsNzZDREo4MkNyWW5BZmVQcGNmNUliRktZRG9nOVpjdEN4aGdDdHhGR1JRYlF2MlZUMVFnSXJFczVvdFpKc1pXYmpnMHdfTzQ4NHhaMVlCM0YzY2NaUHBmd19LQWxuOERLeWFTWU8wRVBQRmlpNFE?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T15:57:39+00:00", "published_display": "17 Jun 2026 15:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRMD: Raised 2026 Guidance And Late-Stage Pipeline Progress Will Support Undervalued Shares", "summary": "CorMedix (CRMD) reported Q1 2026 results, showing significant revenue contributions from DefenCath and raising full-year 2026 net revenue guidance to $325 million to $345 million. The company is also progressing with its REZZAYO pipeline, targeting an sNDA submission to the FDA i", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/czaf0fmb-acquisition-and-pipeline-expansion-will-unlock-healthcare-potential-nalp/updates/16-analysts-trimmed-their-cormedix-price-target-slightly-with", "source_name": "Simply Wall Street", "published_at": "2026-06-17T16:40:43", "published_display": "17 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of CorMedix Inc (CRMD), listing major shareholders and their proportional holdings, such as Deep Track Capital LP and BlackRock. It also categorizes shareholders by type and provides institutional shareholding data over several quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T14:11:04", "published_display": "17 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for CorMedix Inc (CRMD), highlighting that relevant data for business segments and profit contribution have not yet been disclosed by the company. It does, however, indicate a significant portion of revenue, totaling $311.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T13:11:04", "published_display": "17 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxObXA4VWJCWnRUZHgtUUE4bzBMRGRRaW9MZzd0Nnh5RzhkNnJJNGY5NXZCUGhWSEVTOURvejA3SGoxanhqMVE1VDJSYlZEcHRjcVp1WFhJTnlrZDZ6NXkyN2lSbU5NREd6enVzZDdCalhDakQyNmN4VG1XWHVvQ0NNRmJLOWpUYkE0akxnN1E2eFFKbmtpckVsQw?oc=5", "source_name": "Market source", "published_at": "2026-06-17T11:12:17+00:00", "published_display": "17 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "CorMedix Inc (CRMD) has an earnings forecast score of 8.29, ranking 44th in the Pharmaceuticals industry, with an average analyst price target of $20.00. Based on 6 analyst ratings, the company generally receives a \"Buy\" recommendation. The article also provides details on expect", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:11:04", "published_display": "17 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "CorMedix Inc (CRMD) has a robust financial score of 8.94, ranking 25th out of 157 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 226.05% to $127.43 million an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T16:40:43", "published_display": "16 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why", "summary": "CorMedix (CRMD) reported strong Q1 2026 results, with DefenCath driving revenue and management raising guidance for the full year. The company also highlighted progress for REZZAYO, strengthening the investment case despite potential reimbursement pressures for DefenCath after it", "url": "https://uk.finance.yahoo.com/news/bull-case-cormedix-crmd-could-061231486.html", "source_name": "Market source", "published_at": "2026-06-16T05:12:00", "published_display": "16 Jun 2026 05:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake", "summary": "SHAIBATALHAMD AYMEN ABDALKADER has filed an amended Schedule 13G/A, disclosing beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, which represents a 5.89% stake in the company. The filing indicates the holder has sole voting and dispositive power over ", "url": "https://www.stocktitan.net/sec-filings/CRMD/schedule-13g-a-cor-medix-inc-amended-passive-investment-disclosure-09073a0d7c97.html", "source_name": "Stock Titan", "published_at": "2026-06-12T17:38:54", "published_display": "12 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake", "summary": "A Schedule 13G/A filing indicates that investor Aymen Abdalkader Shaibata has reported beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, representing a 5.89% stake. The filing, signed on June 12, 2026, denotes that Shaibata holds sole voting and dispo", "url": "https://www.stocktitan.net/sec-filings/CRMD/schedule-13g-a-cor-medix-inc-amended-passive-investment-disclosure-9bd943273b71.html", "source_name": "Stock Titan", "published_at": "2026-06-12T16:38:54", "published_display": "12 Jun 2026 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Most Profitable Small Cap Stocks to Buy", "summary": "This article highlights CorMedix Inc. (NASDAQ:CRMD) as one of the most profitable small-cap stocks, detailing its Q1 2026 financial performance, including significant revenue and net income growth driven by DefenCath and the acquired Melinta portfolio. The company has raised its ", "url": "https://www.insidermonkey.com/blog/5-most-profitable-small-cap-stocks-to-buy-1778651/2", "source_name": "Insider Monkey", "published_at": "2026-06-11T19:50:00", "published_display": "11 Jun 2026 19:50", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal appeals court upholds CorMedix patent win over Nexus", "summary": "A federal appeals court has affirmed a lower court ruling in favor of CorMedix Therapeutics, stating that Nexus Pharmaceuticals infringed on patents covering MINOCIN for Injection. This decision prevents Nexus from marketing its generic minocycline product until the patents expir", "url": "https://m.uk.investing.com/news/stock-market-news/federal-appeals-court-upholds-cormedix-patent-win-over-nexus-93CH-4717610?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-09T13:38:47", "published_display": "09 Jun 2026 13:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal appeals court upholds CorMedix patent win over Nexus By Investing.com", "summary": "A federal appeals court has affirmed CorMedix Therapeutics' patent victory against Nexus Pharmaceuticals regarding MINOCIN for Injection. The ruling upholds a lower court's decision that Nexus infringed on CorMedix's patents, leading to a permanent injunction preventing Nexus fro", "url": "https://za.investing.com/news/stock-market-news/federal-appeals-court-upholds-cormedix-patent-win-over-nexus-93CH-4318050", "source_name": "Investing.com South Africa", "published_at": "2026-06-09T02:09:06", "published_display": "09 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Court blocks generic rival to hospital antibiotic Minocin, backs CorMedix", "summary": "The U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling that upholds CorMedix Therapeutics' (Nasdaq: CRMD) patents for MINOCIN\u00ae for Injection. The decision also found Nexus Pharmaceuticals' generic minocycline infringing and maintained a permanent injunction", "url": "https://www.stocktitan.net/news/CRMD/u-s-court-of-appeals-for-the-federal-circuit-affirms-victory-for-5cpyf434vs6s.html", "source_name": "Stock Titan", "published_at": "2026-06-08T12:40:08", "published_display": "08 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN\u00ae patents and injunction", "summary": "The U.S. Court of Appeals for the Federal Circuit has affirmed a lower court's judgment that Nexus Pharmaceuticals' generic minocycline product infringes two of CorMedix's MINOCIN\u00ae for Injection patents. The court also upheld a permanent injunction preventing Nexus from marketing", "url": "https://www.stocktitan.net/sec-filings/CRMD/8-k-cor-medix-inc-reports-material-event-fc8132a2febb.html", "source_name": "Stock Titan", "published_at": "2026-06-08T12:40:07", "published_display": "08 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can CorMedix Turn Launch Execution Into Momentum?", "summary": "CorMedix (CRMD) is a specialty pharmaceutical company focused on infection prevention for hemodialysis patients using central venous catheters. The article highlights that its success hinges on effective launch execution, securing reimbursement access, ensuring manufacturing supp", "url": "https://kalkinemedia.com/us/stocks/smallcap/can-cormedix-turn-launch-execution-into-momentum", "source_name": "Kalkine Media", "published_at": "2026-06-06T08:39:52", "published_display": "06 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did CRMD Stock Tumble Over 11% Today?", "summary": "CorMedix Inc.'s (CRMD) stock tumbled over 11% today despite a 312% year-on-year jump in revenue for Q4 2025, reaching $128.6 million largely due to DefenCath sales and the Melinta acquisition. The decline is attributed to an earnings per share (EPS) of $0.16, which significantly ", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-tumble-today/cZdQvWFRI3i", "source_name": "Stocktwits", "published_at": "2026-06-05T12:10:34", "published_display": "05 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets", "summary": "CorMedix Therapeutics (CRMD) is a diversified specialty pharma business experiencing strong growth. This growth is attributed to its robust product portfolio, the successful launch of DefenCath, and the expansion of its pipeline, including label extensions for REZZAYO and new opp", "url": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3378312:0-crmd-strong-growth-driven-by-defencath-rezzayo-and-pipeline-expansion-in-institutional-markets/", "source_name": "TradingView", "published_at": "2026-05-23T06:10:18", "published_display": "23 May 2026 06:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD", "summary": "UBS Group AG significantly reduced its stake in CorMedix Inc. by selling 454,873 shares, cutting its holdings by 41.7% in the fourth quarter. Despite this, CorMedix reported strong quarterly earnings, beating analyst estimates with $0.43 EPS and 226.1% year-over-year revenue grow", "url": "https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-sells-454873-shares-of-cormedix-inc-crmd-2026-05-19/", "source_name": "MarketBeat", "published_at": "2026-05-19T10:40:28", "published_display": "19 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRMD Q1 earnings beat on DefenCath momentum, guidance raised", "summary": "CorMedix (CRMD) reported better-than-expected Q1 earnings, driven by strong sales of DefenCath. The company's net product sales reached $8.7 million, surpassing analyst estimates, prompting an upward revision of its full-year 2026 revenue guidance to $33-38 million. This positive", "url": "https://www.msn.com/en-us/money/topstocks/crmd-q1-earnings-beat-on-defencath-momentum-guidance-raised/ar-AA23hNsC", "source_name": "MSN", "published_at": "2026-05-18T16:39:43", "published_display": "18 May 2026 16:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD)", "summary": "CorMedix remains a \"Sell\" despite its Q1 outperformance, which is considered unsustainable due to non-recurring revenue and anticipated reimbursement challenges for DefenCath. The company faces an 80% sequential revenue decline for DefenCath post-TDAPA, and management's reaffirma", "url": "https://seekingalpha.com/article/4906021-cormedix-long-term-prospects-remain-poor-despite-q1-beat", "source_name": "Seeking Alpha", "published_at": "2026-05-18T14:38:47", "published_display": "18 May 2026 14:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)", "summary": "HC Wainwright has increased its Q2 2026 EPS estimate for CorMedix to $0.26 from $0.21, maintaining a \"Buy\" rating and a $13 price target. This upward revision follows CorMedix's strong Q1 performance, where the company surpassed analyst expectations with $0.43 EPS and a revenue i", "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-cormedixs-q2-earnings-nasdaqcrmd-2026-05-18/", "source_name": "MarketBeat", "published_at": "2026-05-18T05:38:47", "published_display": "18 May 2026 05:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results", "summary": "CorMedix (CRMD) reported strong Q1 2026 results with US$127.43 million in revenue and US$38.6 million in net income, leading to a raised full-year 2026 net revenue guidance of US$325 million to US$345 million. This positive financial update, combined with favorable Phase III resu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/the-bull-case-for-cormedix-crmd-could-change-following-raise", "source_name": "Simply Wall Street", "published_at": "2026-05-17T00:39:58", "published_display": "17 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc reports results for the quarter ended March 31 - Earnings Summary", "summary": "CorMedix Inc has reported its earnings summary for the quarter that concluded on March 31. This brief report, provided by Refinitiv, gives investors and interested parties an overview of the company's financial performance during that period. Additional details may require loggin", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41R1IB:0-cormedix-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-05-15T20:09:39", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership", "summary": "Deep Track-affiliated entities have filed a Schedule 13G/A with the SEC, disclosing a 7.94% beneficial ownership in CorMedix Inc. (CRMD), totaling 6,274,076 shares. The filing indicates shared voting and dispositive power among Deep Track Capital, LP, Deep Track Biotechnology Mas", "url": "https://www.stocktitan.net/sec-filings/CRMD/schedule-13g-a-cor-medix-inc-amended-passive-investment-disclosure-8c90a6a93e13.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:09:49", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biopharmaceutical firm CorMedix plans back-to-back New York investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNVGRkMTJ6WnU0b3I2c0xPaXJ4aGFCVmtTTXRXTVZaVEJ4MENTMUtQT0k4QVp4Q3gxVW8ybXloUjBzczNyYXlPOFMtaGFMY2hMQ0xGY0tMR3pIcjhycTJKVHE3T2hHRWZGVG5uOHJDRU1GQnZXN3o1WVl3SjIybElpMThvWEJnc2FuZ09EU3hLeFNsUDFqZDczM0hVZ1RsMVdGMmtYYlpDUnBOZllvZUw3TFVBeUxPOG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQZkVUR3pBYzRTenJGSW9OeHlzb0thUmlGOUFGekE3akc0UEZ4Tlp6M3BfZ19ESXFDNE4yNExJVDB0dDhMWTRYczU3cGFobXpBQVZmLTZDU2hhQ2UybzBTcldiMjNTMG5McDFYajZkY2lJZlpRTU5DQ3k5SDNSeENPV0pORGk4cFB4VlJmS0tINW5UeWt0N3RMQ19LWVloQnlp?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dialysis drug DefenCath drives $97.5M in Q1 sales as CorMedix lifts 2026 targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOYUdBZE1Sbk9YTlo0OGswSHVaeTQtVFRPUDl2LUZmUy1qWkVIT09tMzVxd1Rfdm92endQRG81am5UUEFMTjYtbUgtZVdLX251WDB5aVpTX3NKc2dBbmFNaWZ6NzVNNkNVYkVtaTJ5YzV1RW9mQWE5YktjU0pCTkZpUDh4VWlYVE9DZGJnU0o1Wk9XaGlOMjJ5eWQ4WkJmRm0zcURlR1lrOXZWVTQ0cFRYUFZ6TFRWOWlHWmdiaDRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The CorMedix (CRMD) Story Is Shifting As Analysts Split On US$13\u2013US$15 Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbWFtaTFacGVFVS1IaWstSnJtN2hHUnNHc2Y5RmZkTE12MVpsSXVydDlfZkw0TF95UUNVOVVXS2VFUmF1TGdBZl9hRjNsUExEOFVoSndjRm9IUkRoVDZNdkFBUlBkaFhhZFo4eEpHQ1VRTW91X0VnQzhrdDF1U3FEOU5GT05OWEZpNmtiV3BPZUk1cU1FMUl0Ymxyd1pOSm5qZF8zeA?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTkpNc2pyN25ZZDlzeHlIRENuck1pWFR1ZmF5LWVOMjAtMHFWX2gtdGxKbDBHT0ZDN1YxaGVONUZMcEZFbi1WWEN6SEdQSVFOTFRjWWMxVHBDaVZ1UkN6N0F2NEJkcGY2SXpwcXRSRzBIYXgxeXRrb0JyODVPS19RbHA2aEJzVzY1R3BBeHJfTm1fMGJ6UzFsWVdhR2xxU3ZQc0p3?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQczhPSV85aEhwazdoMlFuWHYtTXEtaDI5M1V6TkZZYWxiYkZ3Mm9FVGlpaTZpbG1sZjJ6blB0TzYxM3BnNFIwMmZZZk43UDdsZGpBTFlfdy1yYTJpcGtSZ0pWU3luVDJkWTZGWGM4akllYy1mNVdCaFVVWWFNZGtJYldZd1dRZXRSWUphcDZiTGdnNnBnc3MyR1g0akJDYTg3?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPamVrcE90Vm1ycVBLMU9DOGNRR3g5cDRRRjJpUk9VdUlvcEUzWkFXTTNYbkJsVVRrTUY3d0t2aW5sZ0hnWWo0SGxPWXVaX01mZVZxd3ZjMkZyOTRqMkN1dzltTGxHT2VpZk5TNTVxS1lseWJha2VqbE9CWkZtOTNXWnhNNGUxX1NtT3MwTDRzV01PMDhWUDdLRU4xZ2hJMEhZTG8xZk9XQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQRUd1VE85dWN0UEhZUmg5VmZqYVdhSGZxM01QWmlzQWpxSnRackg4dHJoR0kySV80OGl1azNTMUxERU9pX25PMzlMWjJCWVkxVzVkR2hLdG85TGlBck4zeFJfOUpoWGUyMDlYZUV4ZkJ2bVFOQ0NodGpZR1ZNWEFkcTRkdWZwRUlzSnl1Q2NJWQ?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOWTlCbmNzVHRjdEVITkk5NVJIT0FZZXZURVhkNXZ6VWtoUWdMaGxLeF9zVnFfVUdFTHhfbTRoakRYZlJybm5lUDA3Tm44TFlsLTJWM3E1Ukh1RVB5bEQtdFJHYUtyd0NkeGdBT3h2ZjQzY2xhWl9PQU4wUDFLU0VobVhhbEE?oc=5", "source_name": "Market source", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE5IbkJXVUpORktMVmFtNHFGR1hUUVhZVllxRUxyRjBOSm1weThxRXUzY1lkdVZFc19leDR0WGdteWdta0x2dlJxbloyMVJMaDQtRWlfV05XNnV0TUhyNTFwMFl1LW16ZFZ3aDFUWjZYUHNzaHZNamo4N2JORQ?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQQmdGMlBuQk8zZ3g0TnE4RkFWY2xveUFjT05EMnFtRjZQaDg0a0NTNElIM3IzeEFSYThsdEYwRllPSjlDeE56emRPbVZWWmtfUGpKVUlMbTd4UWZPTjFqZUhKZEhEdzdUelFOdkM0ZU5CV2R3empKdDhtQVJNQzBiWUp6d2o?oc=5", "source_name": "Market source", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CorMedix (CRMD) Offering An Opportunity After Its Recent 43% Share Price Slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOZTRQQUxJdmkzWGwzUUhUZlNnb2pvWHAyeFpCUzNfS2lQcm84dXMybWRoUGpaU3lIcEVidmlJTUJ2Q0lYNV9MQVE2SEN2a1Nsb1ZGbWViRXdBalNCQmVYVGgwRXNtWjl2ckZneTJZcEp1X2NQdnZhTmUxUXBFZ3NKNlNETC1fVDM4eE9RQWVITWE?oc=5", "source_name": "Market source", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOVFN3N0w0VlNtYU52b01fUXNab0o1Q2VIWk9Wc1MtU0UtUG5HMHo5WWpYbkRKVGZmSnZWajVoZnZUbjctTWwwVS1IaUQyOVhBYk5hWV9OTXkyUHkwbUR4MXN5TllIVHhhTUdiS1J1b3VaUFFUclEydUlQMzAxdWtqUFVMUDFRS2xKSjhtMW51b0M2Z1draC1nSXZDUi1weG9PUlZFRGVQY2Z6TEVqX004dWlwZENVZjRsZWJyMlFIRmExN3ljUDRjYzJya1VONnRjSXppRFVwY0trTHIzdWI0UU1BMndDWVVTbEFHUUszNWg?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQV214cWstcHBaRkVoQzRGQy1NMVR6Mk0tWUNCS0Niam5pT0o5ODNPUDN0S3ppZG4waEhtdG5jcWNQT1Nrc1VtcmxXRTliVFUwdEh1R2hUMm1KY05la3JmLTRUYkpBLVFiNUlZOWhXZWpUdVlVemQyRHpoN1pwaWl6Y0s4YThUZ0l2RFBjdzhpRQ?oc=5", "source_name": "Market source", "published_at": "2025-12-26T08:00:00+00:00", "published_display": "26 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is CorMedix Stock Rising Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZHVSUldRY214WFI4emFRU3VSY0hFaWRPNW9FR2JnYmNkc3ZWeFZ3T0ZXZ1B5akVERF9qcGxPQl93NkptWGlzYTlzVDZ6VWp3WW9sMmtfLVVjWXdWaGtrTXZMdTU4bW1GQURBbEJWTVNtbGkySjY5eF93RnYzTnlJYThnZWZwUkN2ck1FajdVYjlFaWUybk1zVGlkQm8zWVk?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbDVCVUNxMXhlaGhIN2FtT1BxYThfQUJrRndpZ1RPR2hjSTJESnZnRXN0LWQ2OUwtUnJaWFNXV2F0YVJtclZadUZQRXc3M3lWTXM1a0N6b1NHenRPX1IteGpoTzU0UVRBWXRjZGk5eXM5RlFFZ3Y5Q0Jtcy1nQXBIY3Zna3NwaHVMOHl6S0pONVZ1bG1kTkszTUNENmtYWnFnVDVaaHFta2hPOXIwbjN3cDIxSUwyeXZOQjM3NkZn?oc=5", "source_name": "TradingView", "published_at": "2025-10-14T07:00:00+00:00", "published_display": "14 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-06-27T07:00:00+00:00", "published_display": "27 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (CRMD) Live Share Price, Invest From India", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5Ja0I4NE1hSjdhdFJwc1ZuUVI4Y0MyX2wwbkZHNEViVGQ3WXE2WlBLWl80a1MtZXY4Ql9admdXLU42bklWd0RFNEpOMkhxQWJsbnlVRzUzNWhTdTZCeG5zb3FaSUl5VVNlMGh2a210ZFNtUQ?oc=5", "source_name": "INDmoney", "published_at": "2025-04-18T10:44:51+00:00", "published_display": "18 Apr 2025 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Why (CRMD) Price Action Is Critical for Tactical Trading", "summary": "This article analyzes Cormedix Inc. (CRMD) using AI models, highlighting weak near-term sentiment but strong mid-term indicators within a broader long-term weak bias. It discusses institutional trading strategies, including long, breakout, and short positions, and provides multi-", "url": "https://news.stocktradersdaily.com/news_release/15/Why_CRMD_Price_Action_Is_Critical_for_Tactical_Trading_062126122202_1782015722.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-21T00:41:18", "published_display": "21 Jun 2026 00:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)", "summary": "CorMedix reported strong Q1 2026 results driven by DefenCath and raised its full-year guidance, emphasizing continued business momentum despite the upcoming expiration of temporary TDAPA reimbursement. The company's investment narrative hinges on DefenCath's sustained performance", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/raised-2026-guidance-and-defencath-momentum-might-change-the", "source_name": "Simply Wall Street", "published_at": "2026-06-18T05:09:42", "published_display": "18 Jun 2026 05:09", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (CRMD) Achieves Remarkable 384.60% Revenue Growth", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxOT1QtSUc4U3JIRVhCVWZPb2J0SkI1TktVMmRNcVphcks3QU9hblVhbjlyVl9uMTZwOTdkVUFhaFpsNzZDREo4MkNyWW5BZmVQcGNmNUliRktZRG9nOVpjdEN4aGdDdHhGR1JRYlF2MlZUMVFnSXJFczVvdFpKc1pXYmpnMHdfTzQ4NHhaMVlCM0YzY2NaUHBmd19LQWxuOERLeWFTWU8wRVBQRmlpNFE?oc=5", "source_name": "GuruFocus", "published_at": "2026-06-17T15:57:39+00:00", "published_display": "17 Jun 2026 15:57", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRMD: Raised 2026 Guidance And Late-Stage Pipeline Progress Will Support Undervalued Shares", "summary": "CorMedix (CRMD) reported Q1 2026 results, showing significant revenue contributions from DefenCath and raising full-year 2026 net revenue guidance to $325 million to $345 million. The company is also progressing with its REZZAYO pipeline, targeting an sNDA submission to the FDA i", "url": "https://simplywall.st/community/narratives/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/czaf0fmb-acquisition-and-pipeline-expansion-will-unlock-healthcare-potential-nalp/updates/16-analysts-trimmed-their-cormedix-price-target-slightly-with", "source_name": "Simply Wall Street", "published_at": "2026-06-17T16:40:43", "published_display": "17 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article details the shareholder structure of CorMedix Inc (CRMD), listing major shareholders and their proportional holdings, such as Deep Track Capital LP and BlackRock. It also categorizes shareholders by type and provides institutional shareholding data over several quart", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T14:11:04", "published_display": "17 Jun 2026 14:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article from TradingKey provides a revenue breakdown for CorMedix Inc (CRMD), highlighting that relevant data for business segments and profit contribution have not yet been disclosed by the company. It does, however, indicate a significant portion of revenue, totaling $311.", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T13:11:04", "published_display": "17 Jun 2026 13:11", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) Stock Could Be 27.8% Undervalued After Q1 Results And Raised Outlook", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxObXA4VWJCWnRUZHgtUUE4bzBMRGRRaW9MZzd0Nnh5RzhkNnJJNGY5NXZCUGhWSEVTOURvejA3SGoxanhqMVE1VDJSYlZEcHRjcVp1WFhJTnlrZDZ6NXkyN2lSbU5NREd6enVzZDdCalhDakQyNmN4VG1XWHVvQ0NNRmJLOWpUYkE0akxnN1E2eFFKbmtpckVsQw?oc=5", "source_name": "Market source", "published_at": "2026-06-17T11:12:17+00:00", "published_display": "17 Jun 2026 11:12", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "CorMedix Inc (CRMD) has an earnings forecast score of 8.29, ranking 44th in the Pharmaceuticals industry, with an average analyst price target of $20.00. Based on 6 analyst ratings, the company generally receives a \"Buy\" recommendation. The article also provides details on expect", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/earnings", "source_name": "TradingKey", "published_at": "2026-06-17T12:11:04", "published_display": "17 Jun 2026 12:11", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc (CRMD) Financial Health: Profitability & Balance Sheet Analysis", "summary": "CorMedix Inc (CRMD) has a robust financial score of 8.94, ranking 25th out of 157 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 226.05% to $127.43 million an", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-crmd/financial-health", "source_name": "TradingKey", "published_at": "2026-06-16T16:40:43", "published_display": "16 Jun 2026 16:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why", "summary": "CorMedix (CRMD) reported strong Q1 2026 results, with DefenCath driving revenue and management raising guidance for the full year. The company also highlighted progress for REZZAYO, strengthening the investment case despite potential reimbursement pressures for DefenCath after it", "url": "https://uk.finance.yahoo.com/news/bull-case-cormedix-crmd-could-061231486.html", "source_name": "Market source", "published_at": "2026-06-16T05:12:00", "published_display": "16 Jun 2026 05:12", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake", "summary": "SHAIBATALHAMD AYMEN ABDALKADER has filed an amended Schedule 13G/A, disclosing beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, which represents a 5.89% stake in the company. The filing indicates the holder has sole voting and dispositive power over ", "url": "https://www.stocktitan.net/sec-filings/CRMD/schedule-13g-a-cor-medix-inc-amended-passive-investment-disclosure-09073a0d7c97.html", "source_name": "Stock Titan", "published_at": "2026-06-12T17:38:54", "published_display": "12 Jun 2026 17:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake", "summary": "A Schedule 13G/A filing indicates that investor Aymen Abdalkader Shaibata has reported beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, representing a 5.89% stake. The filing, signed on June 12, 2026, denotes that Shaibata holds sole voting and dispo", "url": "https://www.stocktitan.net/sec-filings/CRMD/schedule-13g-a-cor-medix-inc-amended-passive-investment-disclosure-9bd943273b71.html", "source_name": "Stock Titan", "published_at": "2026-06-12T16:38:54", "published_display": "12 Jun 2026 16:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "5 Most Profitable Small Cap Stocks to Buy", "summary": "This article highlights CorMedix Inc. (NASDAQ:CRMD) as one of the most profitable small-cap stocks, detailing its Q1 2026 financial performance, including significant revenue and net income growth driven by DefenCath and the acquired Melinta portfolio. The company has raised its ", "url": "https://www.insidermonkey.com/blog/5-most-profitable-small-cap-stocks-to-buy-1778651/2", "source_name": "Insider Monkey", "published_at": "2026-06-11T19:50:00", "published_display": "11 Jun 2026 19:50", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal appeals court upholds CorMedix patent win over Nexus", "summary": "A federal appeals court has affirmed a lower court ruling in favor of CorMedix Therapeutics, stating that Nexus Pharmaceuticals infringed on patents covering MINOCIN for Injection. This decision prevents Nexus from marketing its generic minocycline product until the patents expir", "url": "https://m.uk.investing.com/news/stock-market-news/federal-appeals-court-upholds-cormedix-patent-win-over-nexus-93CH-4717610?ampMode=1", "source_name": "Investing.com UK", "published_at": "2026-06-09T13:38:47", "published_display": "09 Jun 2026 13:38", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Federal appeals court upholds CorMedix patent win over Nexus By Investing.com", "summary": "A federal appeals court has affirmed CorMedix Therapeutics' patent victory against Nexus Pharmaceuticals regarding MINOCIN for Injection. The ruling upholds a lower court's decision that Nexus infringed on CorMedix's patents, leading to a permanent injunction preventing Nexus fro", "url": "https://za.investing.com/news/stock-market-news/federal-appeals-court-upholds-cormedix-patent-win-over-nexus-93CH-4318050", "source_name": "Investing.com South Africa", "published_at": "2026-06-09T02:09:06", "published_display": "09 Jun 2026 02:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Court blocks generic rival to hospital antibiotic Minocin, backs CorMedix", "summary": "The U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling that upholds CorMedix Therapeutics' (Nasdaq: CRMD) patents for MINOCIN\u00ae for Injection. The decision also found Nexus Pharmaceuticals' generic minocycline infringing and maintained a permanent injunction", "url": "https://www.stocktitan.net/news/CRMD/u-s-court-of-appeals-for-the-federal-circuit-affirms-victory-for-5cpyf434vs6s.html", "source_name": "Stock Titan", "published_at": "2026-06-08T12:40:08", "published_display": "08 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN\u00ae patents and injunction", "summary": "The U.S. Court of Appeals for the Federal Circuit has affirmed a lower court's judgment that Nexus Pharmaceuticals' generic minocycline product infringes two of CorMedix's MINOCIN\u00ae for Injection patents. The court also upheld a permanent injunction preventing Nexus from marketing", "url": "https://www.stocktitan.net/sec-filings/CRMD/8-k-cor-medix-inc-reports-material-event-fc8132a2febb.html", "source_name": "Stock Titan", "published_at": "2026-06-08T12:40:07", "published_display": "08 Jun 2026 12:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can CorMedix Turn Launch Execution Into Momentum?", "summary": "CorMedix (CRMD) is a specialty pharmaceutical company focused on infection prevention for hemodialysis patients using central venous catheters. The article highlights that its success hinges on effective launch execution, securing reimbursement access, ensuring manufacturing supp", "url": "https://kalkinemedia.com/us/stocks/smallcap/can-cormedix-turn-launch-execution-into-momentum", "source_name": "Kalkine Media", "published_at": "2026-06-06T08:39:52", "published_display": "06 Jun 2026 08:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Did CRMD Stock Tumble Over 11% Today?", "summary": "CorMedix Inc.'s (CRMD) stock tumbled over 11% today despite a 312% year-on-year jump in revenue for Q4 2025, reaching $128.6 million largely due to DefenCath sales and the Melinta acquisition. The decline is attributed to an earnings per share (EPS) of $0.16, which significantly ", "url": "https://stocktwits.com/news-articles/markets/equity/why-did-crmd-stock-tumble-today/cZdQvWFRI3i", "source_name": "Stocktwits", "published_at": "2026-06-05T12:10:34", "published_display": "05 Jun 2026 12:10", "sentiment": "negative", "sentiment_pct": 40, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets", "summary": "CorMedix Therapeutics (CRMD) is a diversified specialty pharma business experiencing strong growth. This growth is attributed to its robust product portfolio, the successful launch of DefenCath, and the expansion of its pipeline, including label extensions for REZZAYO and new opp", "url": "https://www.tradingview.com/news/urn:summary_document_slides:quartr.com:3378312:0-crmd-strong-growth-driven-by-defencath-rezzayo-and-pipeline-expansion-in-institutional-markets/", "source_name": "TradingView", "published_at": "2026-05-23T06:10:18", "published_display": "23 May 2026 06:10", "sentiment": "positive", "sentiment_pct": 91, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD", "summary": "UBS Group AG significantly reduced its stake in CorMedix Inc. by selling 454,873 shares, cutting its holdings by 41.7% in the fourth quarter. Despite this, CorMedix reported strong quarterly earnings, beating analyst estimates with $0.43 EPS and 226.1% year-over-year revenue grow", "url": "https://www.marketbeat.com/instant-alerts/filing-ubs-group-ag-sells-454873-shares-of-cormedix-inc-crmd-2026-05-19/", "source_name": "MarketBeat", "published_at": "2026-05-19T10:40:28", "published_display": "19 May 2026 10:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CRMD Q1 earnings beat on DefenCath momentum, guidance raised", "summary": "CorMedix (CRMD) reported better-than-expected Q1 earnings, driven by strong sales of DefenCath. The company's net product sales reached $8.7 million, surpassing analyst estimates, prompting an upward revision of its full-year 2026 revenue guidance to $33-38 million. This positive", "url": "https://www.msn.com/en-us/money/topstocks/crmd-q1-earnings-beat-on-defencath-momentum-guidance-raised/ar-AA23hNsC", "source_name": "MSN", "published_at": "2026-05-18T16:39:43", "published_display": "18 May 2026 16:39", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD)", "summary": "CorMedix remains a \"Sell\" despite its Q1 outperformance, which is considered unsustainable due to non-recurring revenue and anticipated reimbursement challenges for DefenCath. The company faces an 80% sequential revenue decline for DefenCath post-TDAPA, and management's reaffirma", "url": "https://seekingalpha.com/article/4906021-cormedix-long-term-prospects-remain-poor-despite-q1-beat", "source_name": "Seeking Alpha", "published_at": "2026-05-18T14:38:47", "published_display": "18 May 2026 14:38", "sentiment": "negative", "sentiment_pct": 29, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)", "summary": "HC Wainwright has increased its Q2 2026 EPS estimate for CorMedix to $0.26 from $0.21, maintaining a \"Buy\" rating and a $13 price target. This upward revision follows CorMedix's strong Q1 performance, where the company surpassed analyst expectations with $0.43 EPS and a revenue i", "url": "https://www.marketbeat.com/instant-alerts/hc-wainwright-forecasts-cormedixs-q2-earnings-nasdaqcrmd-2026-05-18/", "source_name": "MarketBeat", "published_at": "2026-05-18T05:38:47", "published_display": "18 May 2026 05:38", "sentiment": "positive", "sentiment_pct": 75, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results", "summary": "CorMedix (CRMD) reported strong Q1 2026 results with US$127.43 million in revenue and US$38.6 million in net income, leading to a raised full-year 2026 net revenue guidance of US$325 million to US$345 million. This positive financial update, combined with favorable Phase III resu", "url": "https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-crmd/cormedix/news/the-bull-case-for-cormedix-crmd-could-change-following-raise", "source_name": "Simply Wall Street", "published_at": "2026-05-17T00:39:58", "published_display": "17 May 2026 00:39", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc reports results for the quarter ended March 31 - Earnings Summary", "summary": "CorMedix Inc has reported its earnings summary for the quarter that concluded on March 31. This brief report, provided by Refinitiv, gives investors and interested parties an overview of the company's financial performance during that period. Additional details may require loggin", "url": "https://www.tradingview.com/news/reuters.com,2026:newsml_L8N41R1IB:0-cormedix-inc-reports-results-for-the-quarter-ended-march-31-earnings-summary/", "source_name": "TradingView", "published_at": "2026-05-15T20:09:39", "published_display": "15 May 2026 20:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership", "summary": "Deep Track-affiliated entities have filed a Schedule 13G/A with the SEC, disclosing a 7.94% beneficial ownership in CorMedix Inc. (CRMD), totaling 6,274,076 shares. The filing indicates shared voting and dispositive power among Deep Track Capital, LP, Deep Track Biotechnology Mas", "url": "https://www.stocktitan.net/sec-filings/CRMD/schedule-13g-a-cor-medix-inc-amended-passive-investment-disclosure-8c90a6a93e13.html", "source_name": "Stock Titan", "published_at": "2026-05-15T12:09:49", "published_display": "15 May 2026 12:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) Q1 Earnings Margin Surge Tests Bearish Narratives", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxNemw4SHdSQ0Y0ckxZc2YyZXEwRU4wSFowTXp2d2dyR0owdVdseG1pYXdTeVZHTGlKZURvMGJJUDNadktkRXhpS3lTdEhiajdkS3BiMzRDNnFXQlVLU2ptY09aQUI5Z0RDRGNDQjRqaHp2RG5mZmhtUkVUU2hTdS1WcEF3dmpRMUxjM29pRWdEbXhyMzRoc0J3SS1TUmxqZDJzZ2VENkgwdmpKc0FFbHlhaUdlS3RhaVczWUd3OEVkMzVEUXhpRTczT09EN1M1b2RSc3diM1RKT2lQZ9IB3wFBVV95cUxOM3pUbTdVaWVJSW01a3MyRHZhTEJtOXY4MkRQUjQtT1AxMGJpNVhfd1V5a3dleS1wYW8wX09sSmhFSFNLSG16ZDBDekJWUldNSm5KZm5jM1h6clFKV29McjAwdlVkdG01YnZIWlpTWWU4cm1zNy10YllDUy1kQ0d4Q2RlS0I3cmlUMzBUNloxY0tJWDF3SE9SMkl5d3dmWE9qWU11Q0VCUlZvYnRueV9Eb2szYjVnenk3eTBTSkVELU1WelJGbHlVOGpqNG50VXI5eUhsNGpGWnhDTS1MUFlv?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Biopharmaceutical firm CorMedix plans back-to-back New York investor talks", "summary": "", "url": "https://news.google.com/rss/articles/CBMitwFBVV95cUxNVGRkMTJ6WnU0b3I2c0xPaXJ4aGFCVmtTTXRXTVZaVEJ4MENTMUtQT0k4QVp4Q3gxVW8ybXloUjBzczNyYXlPOFMtaGFMY2hMQ0xGY0tMR3pIcjhycTJKVHE3T2hHRWZGVG5uOHJDRU1GQnZXN3o1WVl3SjIybElpMThvWEJnc2FuZ09EU3hLeFNsUDFqZDczM0hVZ1RsMVdGMmtYYlpDUnBOZllvZUw3TFVBeUxPOG8?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) Q1 Earnings and Revenues Beat Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQZkVUR3pBYzRTenJGSW9OeHlzb0thUmlGOUFGekE3akc0UEZ4Tlp6M3BfZ19ESXFDNE4yNExJVDB0dDhMWTRYczU3cGFobXpBQVZmLTZDU2hhQ2UybzBTcldiMjNTMG5McDFYajZkY2lJZlpRTU5DQ3k5SDNSeENPV0pORGk4cFB4VlJmS0tINW5UeWt0N3RMQ19LWVloQnlp?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Dialysis drug DefenCath drives $97.5M in Q1 sales as CorMedix lifts 2026 targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxOYUdBZE1Sbk9YTlo0OGswSHVaeTQtVFRPUDl2LUZmUy1qWkVIT09tMzVxd1Rfdm92endQRG81am5UUEFMTjYtbUgtZVdLX251WDB5aVpTX3NKc2dBbmFNaWZ6NzVNNkNVYkVtaTJ5YzV1RW9mQWE5YktjU0pCTkZpUDh4VWlYVE9DZGJnU0o1Wk9XaGlOMjJ5eWQ4WkJmRm0zcURlR1lrOXZWVTQ0cFRYUFZ6TFRWOWlHWmdiaDRB?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The CorMedix (CRMD) Story Is Shifting As Analysts Split On US$13\u2013US$15 Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxQbWFtaTFacGVFVS1IaWstSnJtN2hHUnNHc2Y5RmZkTE12MVpsSXVydDlfZkw0TF95UUNVOVVXS2VFUmF1TGdBZl9hRjNsUExEOFVoSndjRm9IUkRoVDZNdkFBUlBkaFhhZFo4eEpHQ1VRTW91X0VnQzhrdDF1U3FEOU5GT05OWEZpNmtiV3BPZUk1cU1FMUl0Ymxyd1pOSm5qZF8zeA?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix (CRMD) Earnings Expected to Grow: What to Know Ahead of Next Week's Release", "summary": "", "url": "https://news.google.com/rss/articles/CBMiowFBVV95cUxQTkpNc2pyN25ZZDlzeHlIRENuck1pWFR1ZmF5LWVOMjAtMHFWX2gtdGxKbDBHT0ZDN1YxaGVONUZMcEZFbi1WWEN6SEdQSVFOTFRjWWMxVHBDaVZ1UkN6N0F2NEJkcGY2SXpwcXRSRzBIYXgxeXRrb0JyODVPS19RbHA2aEJzVzY1R3BBeHJfTm1fMGJ6UzFsWVdhR2xxU3ZQc0p3?oc=5", "source_name": "Market source", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The CorMedix (CRMD) Story Is Shifting With Lower Guidance And Mixed Analyst Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMioAFBVV95cUxQczhPSV85aEhwazdoMlFuWHYtTXEtaDI5M1V6TkZZYWxiYkZ3Mm9FVGlpaTZpbG1sZjJ6blB0TzYxM3BnNFIwMmZZZk43UDdsZGpBTFlfdy1yYTJpcGtSZ0pWU3luVDJkWTZGWGM4akllYy1mNVdCaFVVWWFNZGtJYldZd1dRZXRSWUphcDZiTGdnNnBnc3MyR1g0akJDYTg3?oc=5", "source_name": "Market source", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "guidance", "event_label": "Guidance", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The CorMedix (CRMD) Investment Story Is Shifting As Analyst Targets Reset", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxPamVrcE90Vm1ycVBLMU9DOGNRR3g5cDRRRjJpUk9VdUlvcEUzWkFXTTNYbkJsVVRrTUY3d0t2aW5sZ0hnWWo0SGxPWXVaX01mZVZxd3ZjMkZyOTRqMkN1dzltTGxHT2VpZk5TNTVxS1lseWJha2VqbE9CWkZtOTNXWnhNNGUxX1NtT3MwTDRzV01PMDhWUDdLRU4xZ2hJMEhZTG8xZk9XQQ?oc=5", "source_name": "Market source", "published_at": "2026-03-24T07:00:00+00:00", "published_display": "24 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CorMedix (CRMD) Now Offering Value After Sharp Share Price Declines?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-03-19T07:00:00+00:00", "published_display": "19 Mar 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing CorMedix (CRMD) Valuation After Recent Share Price Weakness And Growth Expectations", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQRUd1VE85dWN0UEhZUmg5VmZqYVdhSGZxM01QWmlzQWpxSnRackg4dHJoR0kySV80OGl1azNTMUxERU9pX25PMzlMWjJCWVkxVzVkR2hLdG85TGlBck4zeFJfOUpoWGUyMDlYZUV4ZkJ2bVFOQ0NodGpZR1ZNWEFkcTRkdWZwRUlzSnl1Q2NJWQ?oc=5", "source_name": "Market source", "published_at": "2026-03-06T08:00:00+00:00", "published_display": "06 Mar 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Time To Revisit CorMedix (CRMD) After Its Sharp Year To Date Decline?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxOWTlCbmNzVHRjdEVITkk5NVJIT0FZZXZURVhkNXZ6VWtoUWdMaGxLeF9zVnFfVUdFTHhfbTRoakRYZlJybm5lUDA3Tm44TFlsLTJWM3E1Ukh1RVB5bEQtdFJHYUtyd0NkeGdBT3h2ZjQzY2xhWl9PQU4wUDFLU0VobVhhbEE?oc=5", "source_name": "Market source", "published_at": "2026-03-01T08:00:00+00:00", "published_display": "01 Mar 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Expands With Melinta Buy As Valuation Gap Draws Attention", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-28T08:00:00+00:00", "published_display": "28 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Down 27% in 3 Months: Is It Time to Sell the Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMie0FVX3lxTE5IbkJXVUpORktMVmFtNHFGR1hUUVhZVllxRUxyRjBOSm1weThxRXUzY1lkdVZFc19leDR0WGdteWdta0x2dlJxbloyMVJMaDQtRWlfV05XNnV0TUhyNTFwMFl1LW16ZFZ3aDFUWjZYUHNzaHZNamo4N2JORQ?oc=5", "source_name": "Market source", "published_at": "2026-02-17T08:00:00+00:00", "published_display": "17 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (CRMD) Board Approves Multi-Year $75M Stock Buyback", "summary": "", "url": "https://news.google.com/rss/articles/CBMihAFBVV95cUxQQmdGMlBuQk8zZ3g0TnE4RkFWY2xveUFjT05EMnFtRjZQaDg0a0NTNElIM3IzeEFSYThsdEYwRllPSjlDeE56emRPbVZWWmtfUGpKVUlMbTd4UWZPTjFqZUhKZEhEdzdUelFOdkM0ZU5CV2R3empKdDhtQVJNQzBiWUp6d2o?oc=5", "source_name": "Market source", "published_at": "2026-02-11T08:00:00+00:00", "published_display": "11 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (NASDAQ:CRMD) Not Doing Enough For Some Investors As Its Shares Slump 35%", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2AFBVV95cUxNWEYzTG5NSnEwb3VTMFZ5dnFuSzc3VTdFeXJ3ZUU2NE9iX2pWZUZBTzNpVDdTcnc3eWh3b3drNGhSWWd2b3U1a1RwRkpydHYwTDN4WHZjcnhxYk51aUN0NVRmN1VkN2tFYWtCVHdaU2xaZEpZM2Z5d0JaanZXVVczQTJ3azRaQm9rUmU1SmdUMlpVMlpEZDRKMEMzV0lNRTNVNnJLZ2RBVTNEYnpDdm01ajJpN1JKQWl1ZTNTdktDbXgtMmd1bEdSVG5mSDFEYmJDc09MTWI2SjfSAd4BQVVfeXFMTkZWMExBZktDbWlNUU9NNHZPemdkNVZUWVRRRWZVNjR0VUF2U1JPQjVnOUsyLVpJUHo2MG5TdV9OV3BuRDNxOFU5VzE4T3I5aDVPU0tXVTRRcmZhbHR3aTlpNXVDbEV3cE41ZDJWZ2REck5GWTBwc1AxeG9uYVlzWWZ0dFFISXJLWEt3VkI2RW9qLVUwazYwbUkxVWs1LTdnQW5ickd5TWVWOVBkRkQ5eml3Tm03UlN3TDBuNHF3aFRTYUlacVFWYVRZazFEaVFrcDRHTHFUdEN2VURuNEpR?oc=5", "source_name": "simplywall.st", "published_at": "2026-02-06T08:00:00+00:00", "published_display": "06 Feb 2026 08:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is CorMedix (CRMD) Offering An Opportunity After Its Recent 43% Share Price Slide", "summary": "", "url": "https://news.google.com/rss/articles/CBMikAFBVV95cUxOZTRQQUxJdmkzWGwzUUhUZlNnb2pvWHAyeFpCUzNfS2lQcm84dXMybWRoUGpaU3lIcEVidmlJTUJ2Q0lYNV9MQVE2SEN2a1Nsb1ZGbWViRXdBalNCQmVYVGgwRXNtWjl2ckZneTJZcEp1X2NQdnZhTmUxUXBFZ3NKNlNETC1fVDM4eE9RQWVITWE?oc=5", "source_name": "Market source", "published_at": "2026-01-20T08:00:00+00:00", "published_display": "20 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Stock Rises After-Hours: CEO Locks In Chairman Seat, Bigger Paycheck And Rich Severance", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxOVFN3N0w0VlNtYU52b01fUXNab0o1Q2VIWk9Wc1MtU0UtUG5HMHo5WWpYbkRKVGZmSnZWajVoZnZUbjctTWwwVS1IaUQyOVhBYk5hWV9OTXkyUHkwbUR4MXN5TllIVHhhTUdiS1J1b3VaUFFUclEydUlQMzAxdWtqUFVMUDFRS2xKSjhtMW51b0M2Z1draC1nSXZDUi1weG9PUlZFRGVQY2Z6TEVqX004dWlwZENVZjRsZWJyMlFIRmExN3ljUDRjYzJya1VONnRjSXppRFVwY0trTHIzdWI0UU1BMndDWVVTbEFHUUszNWg?oc=5", "source_name": "Stocktwits", "published_at": "2026-01-09T08:00:00+00:00", "published_display": "09 Jan 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?", "summary": "", "url": "https://news.google.com/rss/articles/CBMijwFBVV95cUxQV214cWstcHBaRkVoQzRGQy1NMVR6Mk0tWUNCS0Niam5pT0o5ODNPUDN0S3ppZG4waEhtdG5jcWNQT1Nrc1VtcmxXRTliVFUwdEh1R2hUMm1KY05la3JmLTRUYkpBLVFiNUlZOWhXZWpUdVlVemQyRHpoN1pwaWl6Y0s4YThUZ0l2RFBjdzhpRQ?oc=5", "source_name": "Market source", "published_at": "2025-12-26T08:00:00+00:00", "published_display": "26 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 77, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Is CorMedix Stock Rising Today?", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxNZHVSUldRY214WFI4emFRU3VSY0hFaWRPNW9FR2JnYmNkc3ZWeFZ3T0ZXZ1B5akVERF9qcGxPQl93NkptWGlzYTlzVDZ6VWp3WW9sMmtfLVVjWXdWaGtrTXZMdTU4bW1GQURBbEJWTVNtbGkySjY5eF93RnYzTnlJYThnZWZwUkN2ck1FajdVYjlFaWUybk1zVGlkQm8zWVk?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-18T08:00:00+00:00", "published_display": "18 Dec 2025 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Stock Plunges 16% in a Month: Should Investors Buy the Dip?", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxQbDVCVUNxMXhlaGhIN2FtT1BxYThfQUJrRndpZ1RPR2hjSTJESnZnRXN0LWQ2OUwtUnJaWFNXV2F0YVJtclZadUZQRXc3M3lWTXM1a0N6b1NHenRPX1IteGpoTzU0UVRBWXRjZGk5eXM5RlFFZ3Y5Q0Jtcy1nQXBIY3Zna3NwaHVMOHl6S0pONVZ1bG1kTkszTUNENmtYWnFnVDVaaHFta2hPOXIwbjN3cDIxSUwyeXZOQjM3NkZn?oc=5", "source_name": "TradingView", "published_at": "2025-10-14T07:00:00+00:00", "published_display": "14 Oct 2025 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bullish: Analysts Just Made A Meaningful Upgrade To Their CorMedix Inc. (NASDAQ:CRMD) Forecasts", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-06-27T07:00:00+00:00", "published_display": "27 Jun 2025 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CorMedix Inc. (CRMD) Live Share Price, Invest From India", "summary": "", "url": "https://news.google.com/rss/articles/CBMickFVX3lxTE5Ja0I4NE1hSjdhdFJwc1ZuUVI4Y0MyX2wwbkZHNEViVGQ3WXE2WlBLWl80a1MtZXY4Ql9admdXLU42bklWd0RFNEpOMkhxQWJsbnlVRzUzNWhTdTZCeG5zb3FaSUl5VVNlMGh2a210ZFNtUQ?oc=5", "source_name": "INDmoney", "published_at": "2025-04-18T10:44:51+00:00", "published_display": "18 Apr 2025 10:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "With EPS Growth And More, Puma Biotechnology (NASDAQ:PBYI) Makes An Interesting Case", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2025-12-09T08:00:00+00:00", "published_display": "09 Dec 2025 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 94, "total_relevant": 56, "sentiment_summary": {"positive": 24, "negative": 8, "neutral": 24, "score": 59, "total": 56, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 13.14, "count": 25}, {"event": "general", "label": "Market update", "weight": 12.65, "count": 23}, {"event": "deals", "label": "Deals and strategy", "weight": 2.2, "count": 4}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "guidance", "label": "Guidance", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 24, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 8.67, "latest_week": "2026-06-19", "one_week_move": -0.8, "four_week_move": 8.6, "twelve_week_move": 29.2, "trend_signal": "0", "trend_label": "Trend inactive", "trend_tone": "negative", "market_dynamics": 0.908588, "market_dynamics_buy_signal": false, "relative_strength": -26.538249, "fair_value_gap": 14.6, "fair_value_label": "Near fair-value range", "fair_value_tone": "neutral", "expectation_direction": "undecided", "expectation_probability": 53.4159, "reaction_label": "Price digesting", "reaction_tone": "neutral", "market_sentence": "-0.8% over one week, +8.6% over four weeks, trend inactive, and near fair-value range."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 57, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 18}, {"label": "Stock Titan", "count": 7}, {"label": "simplywall.st", "count": 7}, {"label": "TradingKey", "count": 4}, {"label": "Simply Wall Street", "count": 3}, {"label": "Stocktwits", "count": 3}, {"label": "TradingView", "count": 3}, {"label": "MarketBeat", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 49}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 25}, {"label": "Market update", "count": 23}, {"label": "Deals and strategy", "count": 4}, {"label": "Analyst action", "count": 2}, {"label": "Guidance", "count": 1}, {"label": "Capital return", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "49", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend inactive", "tone": "negative", "text": "-0.8% over one week, +8.6% over four weeks, trend inactive, and near fair-value range."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Why (CRMD) Price Action Is Critical for Tactical Trading"}], "updated_at": "2026-06-22T19:32:50.833746+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}